Completed PHASE1 INTERVENTIONAL 2-arm NCT02185846

Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fed Condition

Comparative, Randomized, Two -Period, Two-treatment, Two -Sequence, Open Label, Crossover Bioequivalence Pilot Study of Dirithromycin 500 mg Enteric Coated Tablet (One Tablet) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) Versus Dynabac 250 mg Enteric Coated Tablet (Two Tablets) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fed Conditions.

Sponsor: Abdi Ibrahim Ilac San. ve Tic A.S.

Conditions Healthy

Interventions DIRITHROMYCIN 500 MG ENTERIC COATED TABLET DYNABAC 250 MG ENTERIC COATED TABLET

Updated 5 times since 2017 Last updated: Jul 9, 2014 Started: Jun 30, 2014 Primary completion: Jun 30, 2014 Completion: Jun 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Abdi Ibrahim Ilac San. ve Tic A.S. and has accumulated 5 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abdi Ibrahim Ilac San. ve Tic A.S.
Pharmaceutical Research Unit, Jordan

Data source: Pharmaceutical Research Unit, Jordan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Amman, Jordan